Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count

Post Date:

2011-03-27

Countries:

Ethiopia

India

Uganda

Clinical Sites:

BJGMC

Publication:

AIDS Care

Summary:

Objectives: We previously reported combined analysis of 6-week and 6-month endpoints of three randomized controlled trials [Six Week Extended Dose Nevirapine (SWEN) trials] that compared extended-dose nevirapine through 6 weeks of age to single-dose nevirapine to prevent HIV transmission via breastfeeding and mortality. We now present endpoints through 12 months of age.

Design: Infants in Ethiopia, India, and Uganda born to HIV-infected women who chose to breastfeed were randomized to receive single-dose or extended-dose nevirapine.

Citation:

Omer S, for the Six Week Extended Dose Nevirapine (SWEN) Study Team. Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS Care. 2011 Mar 27; 25:767-776.

Staff:

Bob Bollinger, MD, MPH

Amita Gupta, MD, MHS

Nikhil Gupte, PhD

Nishi Suryavanshi, PhD

Collaborators:

Addis Ababa University, Addis Ababa, Ethiopia
BJGMC, Pune, India
ICMR/National AIDS Research Institute, Pune, India
Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda
NIH/NIAID, Bethesda, MD